Business
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology
- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\n- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines of Therapy\n\n- Clinically Significant Activity in Subjects Previously Treated with Autologous CD19 Directed CAR T\n\n- In B-ALL Subjects Enhanced Lymphodepletion or Higher Doses of PBCAR0191 Resulted in High Complete Response Rates Allowing the Potential to Bridge to Allogeneic Stem Cell Transplant\n\n- Data Presented at ASH will be Updated to Include Subjects with >28 Day Follow up as of October 10, 2021\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that investigators involved with the Phase 1/2a study of PBCAR0191 in Relapsed/Refractory (R/R) non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL), will present new data during two oral presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place December 11-14, 2021.\n\n“We are encouraged by the response rates seen in this heavily pre-treated patient population, and that a treatment strategy with enhanced lymphodepletion mitigated PBCAR0191 rejection and improved peak CAR T cell expansion and persistence, compared to standard lymphodepletion, with predictable toxicity,” said Alan List, MD, Chief Medical Officer of Precision BioSciences. “We look forward to sharing additional patient outcome, durability, and safety data for PBCAR0191 at the American Society of Hematology Annual Meeting.”\n\nThe abstracts accepted by the ASH are now available at www.hematology.org, and will be presented during the following oral presentation sessions:\n\nSession Name: 626, Abstract #302. Aggressive Lymphomas Prospective Therapeutic Trials: Challenging Populations\nOral Presentation Title: Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-cell Malignancies\nPresenting Author: Bijal Shah, M.D., Moffitt Cancer Center\nDate/Time: Saturday, December 11, 2021 at 4:15 PM ET\nLocation: Georgia World Congress Center, B401-B402\n\nSession Name: 704, Abstract #650 Cellular Immunotherapies: Allog...